Low-dose Prempro approval
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Wyeth plans early summer 2003 launch for low-dose formulation of Prempro (0.45 mg conjugated estrogens/1.5 mg medroxyprogesterone). The March 12 approval is based on the 2,805-patient HOPE study, which found the lower dose to be as effective as the 0.625 mg/2.5 mg dose in treating vasomotor symptoms and vaginal atrophy. The approval gives Wyeth the first positive news in hormone therapy since the Women's Health Initiative Prempro study arm was halted in July 2002 due to an increased risk of breast cancer and adverse cardiovascular outcomes. The firm is also pursuing a 0.3/1.5 formulation, with approval expected as early as Septembe
You may also be interested in...
Wyeth’s second low-dose HRT
Wyeth plans to launch low-dose Premarin (.45 mg estrogens) this summer along with the recently approved low-dose PremPro (.45 mg estrogens/1.5 mg medroxyprogesterone). FDA cleared the Premarin formulation April 25; low-dose PremPro was approved March 12 (1Pharmaceutical Approvals Monthly April 1, In Brief). The product's estrogen content is 28% less than the standard .625 mg dose, which Wyeth says allows for "better individualization of therapy, particularly for new patients." The firm hopes that the low-dose products will allay concerns stemming from the Women's Health Initiative stud
Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says
The statement, which is part of a final rule on the 340B administrative dispute resolution process, could facilitate manufacturer efforts to seek repayments from hospitals in such cases.
The Aspirin Test For AI?
US FDA Commissioner Robert Califf tells Congress that regulators don’t have to know how artificial intelligence works in medicine, but must make very sure it actually does work.